Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Has Average Price Target of $103.33

17 Oct 2026, 10:45 by Amy Steele · The Cerbat Gem

Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Get Free Report) has been assigned an average rating of “Hold” from the twenty-two research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $103.33.

Several equities research analysts have recently commented on the stock. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 25th. Robert W. Baird set a $104.00 price objective on shares of Zimmer Biomet in a research note on Thursday, August 6th. Canaccord Genuity Group lifted their price objective on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Finally, Truist Financial boosted their price objective on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a research note on Thursday, August 6th.

Read Our Latest Research Report on Zimmer Biomet

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Chad F. Phipps sold 3,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 1.28% of the company’s stock.

Institutional Trading of Zimmer Biomet

Institutional investors have recently modified their holdings of the company. Tacita Capital Inc purchased a new stake in Zimmer Biomet in the 2nd quarter worth $26,000. Monetary Solutions Ltd acquired a new position in Zimmer Biomet during the fourth quarter worth $30,000. Ancora Advisors LLC acquired a new position in Zimmer Biomet during the second quarter worth $29,000. Elevation Wealth Partners LLC lifted its holdings in Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 229 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC purchased a new position in Zimmer Biomet during the first quarter valued at $44,000. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Stock Up 0.6%

Shares of ZBH traded up $0.52 during midday trading on Friday, reaching $94.90. 1,935,274 shares of the stock were exchanged, compared to its average volume of 2,126,925. The company has a market capitalization of $18.10 billion, a P/E ratio of 23.09, a PEG ratio of 1.78 and a beta of 0.49. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet has a 52 week low of $79.12 and a 52 week high of $106.88. The company’s 50 day moving average is $95.31 and its two-hundred day moving average is $91.29.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the previous year, the company posted $2.07 earnings per share. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.54 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.36%.

Zimmer Biomet Company Profile

(Get Free Report)

Zimmer Biomet Holdings, Inc (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. The company develops, manufactures and markets products used in orthopedic surgery, including total and partial knee, hip and shoulder replacement systems, sports medicine products, extremities, trauma devices and related surgical technologies.